Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMF followed by tamoxifen versus tamoxifen alone in postmenopausal node-negative estrogen receptor-positive breast cancer
ACTRN12607000029493Phase 3Completed
- Sponsor
- International Breast Cancer Study Group
- Start
- Apr 1989
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, cyclophosphamide, methotrexate and fluorouracil in breast cancer (2 arms), sponsored by International Breast Cancer Study Group. Primary endpoint: Disease-free survival. Started Apr 1989; status: completed.
02
Drugs
tamoxifencyclophosphamidemethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000029493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000029493.